Syngulon Bacteriocins

Gallery Syngulon Bacteriocins 1
Gallery Syngulon Bacteriocins 1
May 2021
Headquarters 4102 Seraing, Belgium

Syngulon Bacteriocins - Cost-effective antibiotic-free microbial selection to boost fermentation production

The increasing regulatory requirements to which biological agents are subjected will have a great impact on all industries that use microbial fermentation-based production. There is an expectation that in the near future, zero-tolerance will apply to antibiotics. Besides the antibiotic itself, avoidance of using antibiotic resistance genes is clearly of critical importance because their complete absence is the only way to avoid their propagation in the environment or transfer of resistance to pathogenic bacteria. Syngulon antibiotic-free selection technology is based on the use of bacteriocins, discovered in 1925 by Belgian scientist Andre Gratia, that are natural antimicrobial peptide. Syngulon Solution is a cost-effective, antibiotic-free selection innovation to boost microbial fermentation.

Key features

  • 100% reduction of antibiotic and antibiotic-resistance gene in the process and therefore in the environment - critical as Antimicrobial Resistance (AMR) is an increasingly serious threat to global public health
  • At least 20% energy reduction due to increased efficiency of fermentation-based production


  • At least 25% yield increase for use in pharma, cosmetics or enzyme production industries when produced by microbial fermentation
  • Payback time of maximum 3 years

Maturity Stage

  • Medium and large scale commercialization
  • Small scale commercialization
  • Initial market commercialization
  • Prototype testing in the real world
  • Prototype testing 1:1 in the lab

Looking For

Activity Region

  • /

North america

United States,

  • Headquarters
  • Activity

Related Topics

The information set out above, is solely for the purposes of information and the Solar Impulse Foundation does not provide any guarantee as to its authenticity, completeness or accuracy. This information does not constitute investment advice or a recommendation to buy into, transact or to enter into any agreement with any of the parties or persons mentioned above. Potential investors or interested parties are solely responsible for their investment or business decisions and for performing any due diligence required by the circumstances.